단백질 검출 및 정량화 시장 - 세계 예측(2026-2032년)

The Protein Detection & Quantification Market is projected to grow by USD 5.57 billion at a CAGR of 7.89% by 2032.

Protein detection and quantification are foundational to modern life science research, clinical diagnostics, biopharmaceutical development, food safety testing, and environmental monitoring. The field spans immunoassays, western blotting, mass spectrometry, chromatography, spectrophotometry, fluorescence-based assays, capillary electrophoresis, label-free biosensors, and multiplex proteomic workflows. Demand is being shaped by the expanding role of proteomics in biomarker discovery, precision medicine, vaccine and biologics development, cell and gene therapy characterization, and quality control for complex biological products.

The scientific importance of protein analysis continues to rise because proteins are direct functional mediators of cellular activity. Unlike genomic data, protein abundance, post-translational modifications, localization, folding, and interaction networks provide dynamic insight into disease biology and therapeutic response. This makes reliable protein detection and quantification essential for translational research, drug discovery, companion diagnostics, and regulated bioanalytical testing. Across laboratories, the priority is shifting toward higher sensitivity, improved reproducibility, lower sample volume, stronger automation, digital traceability, and compatibility with complex matrices such as plasma, serum, tissue lysates, cell culture media, and single-cell samples.

Transformative Shifts in the Protein Analysis Landscape

The protein detection and quantification landscape is being reshaped by the convergence of high-throughput proteomics, miniaturized assay formats, automated sample preparation, and advanced data analytics. Laboratories are moving beyond single-analyte measurement toward multiplexed and spatially resolved protein analysis, enabling researchers to capture pathway-level changes and tissue-specific biological context. This shift is especially relevant for oncology, immunology, neurology, infectious disease research, and inflammatory disease profiling, where protein signatures often provide clinically meaningful insights.

Mass spectrometry-based proteomics is gaining importance for unbiased protein identification, targeted quantification, and post-translational modification analysis, while immunoassay platforms remain widely used for routine sensitivity, scalability, and clinical workflow familiarity. Digital immunoassays and ultrasensitive detection technologies are extending the lower limits of detection for low-abundance biomarkers, while microfluidics and lab-on-chip systems are reducing reagent consumption and enabling faster workflows. In parallel, regulatory expectations for assay validation, data integrity, and reproducibility are pushing laboratories to standardize protocols, improve reference material use, and adopt quality management practices aligned with clinical and biopharmaceutical requirements.

Cumulative Impact of Artificial Intelligence on Protein Quantification

Artificial intelligence is increasingly influencing protein detection and quantification by improving experimental design, image analysis, mass spectrometry interpretation, protein structure-function assessment, and biomarker pattern recognition. In proteomics workflows, AI and machine learning models support peptide-spectrum matching, signal deconvolution, missing-value imputation, batch effect correction, and classification of disease-associated protein signatures. These capabilities are particularly valuable in high-dimensional datasets generated by multiplex immunoassays, LC-MS/MS, spatial proteomics, and single-cell protein analysis.

AI also contributes to automation and decision support in laboratory operations. Intelligent systems can flag anomalous assay results, optimize instrument parameters, improve quality control review, and reduce manual interpretation bias. In biomarker discovery, machine learning enables integration of proteomic data with genomics, transcriptomics, metabolomics, imaging, and clinical records, supporting more robust biological interpretation. However, adoption depends on transparent model validation, curated reference datasets, standardized metadata, cybersecurity controls, and compliance with applicable data governance requirements. The strongest impact is expected where AI augments expert interpretation rather than replacing scientific validation.

Key Regional Insights Across Protein Detection & Quantification

Asia-Pacific is advancing rapidly in protein detection and quantification due to expanding biomedical research infrastructure, government-supported life science initiatives, growing biopharmaceutical manufacturing, and rising adoption of precision medicine. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening proteomics capacity through academic research programs, clinical trial activity, biosimilar development, and infectious disease surveillance. Regional laboratories are increasingly adopting automated immunoassay systems, LC-MS/MS platforms, high-throughput protein analysis, and quality-controlled workflows to support translational research, biologics characterization, and clinical laboratory modernization.

North America remains a highly mature environment for protein detection technologies, supported by strong biomedical funding, advanced clinical laboratory networks, regulated biopharmaceutical development, and extensive use of proteomics in drug discovery and biomarker validation. The United States and Canada emphasize assay reproducibility, laboratory accreditation, advanced bioinformatics, and translational applications in oncology, immunology, metabolic disease, and neurological disorders. Latin America is developing protein analysis capabilities through public health diagnostics, academic research, food safety testing, and expanding clinical laboratory modernization, with Brazil and Mexico serving as important regional contributors for immunoassay adoption, vaccine-related testing, and pharmaceutical quality control.

Europe benefits from established research universities, clinical biobanking networks, strict quality standards, and coordinated biomedical research programs. The region shows strong adoption of standardized workflows for clinical proteomics, biologics testing, and disease biomarker research, particularly in Germany, France, the United Kingdom, Italy, and Spain. The Middle East is investing in healthcare modernization, genomic medicine programs, and clinical laboratory capacity, creating opportunities for advanced protein diagnostics, automated immunoassays, and translational research. Africa's protein detection landscape is shaped by infectious disease testing, public health laboratory strengthening, agricultural biotechnology, and research partnerships, with gradual expansion in molecular, immunoassay, and protein biomarker infrastructure across major academic and healthcare centers.

Key Group Insights for Protein Detection & Quantification

ASEAN is becoming increasingly relevant for protein detection and quantification as member countries expand diagnostic capacity, biomedical research, vaccine-related infrastructure, and food safety testing. The region's emphasis on healthcare access, infectious disease monitoring, and biomanufacturing readiness supports adoption of reliable immunoassay and molecular laboratory workflows. GCC countries are investing in advanced healthcare systems, national research programs, and precision medicine infrastructure, creating demand for high-quality protein biomarker analysis, clinical immunoassays, automated laboratory platforms, and interoperable diagnostic data systems.

The European Union has a strong influence on protein analysis through harmonized regulatory frameworks, research funding mechanisms, clinical laboratory quality systems, and collaborative biomedical research networks. EU priorities around data protection, in vitro diagnostic regulation, and research reproducibility are shaping assay validation and laboratory adoption practices. BRICS countries collectively contribute through large patient populations, expanding pharmaceutical manufacturing, public health diagnostics, and growing academic proteomics programs. China and India are particularly important for scale and biomanufacturing depth, while Brazil, Russia, and South Africa contribute through regional research, infectious disease programs, agricultural biotechnology, and healthcare modernization priorities.

G7 countries are central to advanced protein detection and quantification due to well-developed research ecosystems, high clinical testing standards, mature biopharmaceutical sectors, and early adoption of high-resolution analytical technologies. These economies drive innovation in mass spectrometry, multiplex assays, biomarker qualification, and regulated biologics characterization. NATO member countries, many of which overlap with advanced life science economies, support protein analysis through defense health research, biosecurity preparedness, infectious disease surveillance, toxicology research, and dual-use biotechnology governance. Across all groups, the common direction is toward standardized, automated, ultrasensitive, and data-integrated protein measurement workflows.

Key Country Insights in Protein Detection & Quantification

The United States leads in advanced protein detection and quantification applications due to its dense network of biomedical research institutions, clinical laboratories, biopharmaceutical developers, and regulatory science expertise. Canada supports strong proteomics research, oncology biomarker studies, and public health laboratory modernization. Mexico is expanding clinical testing and biomedical research capabilities, with growing relevance in diagnostics, pharmaceutical quality control, and academic life science programs. Brazil has a significant role in Latin America through public health research, vaccine production capabilities, clinical diagnostics, and agricultural biotechnology applications.

The United Kingdom has a strong position in translational proteomics, clinical research, population health studies, and biomarker discovery supported by research-intensive universities and healthcare-linked datasets. Germany demonstrates robust capability in analytical instrumentation use, biopharmaceutical process control, clinical chemistry, and regulated laboratory practice. France contributes through immunology, oncology, infectious disease research, and national biomedical research programs. Russia maintains capabilities in academic biochemistry, clinical diagnostics, and biotechnology research, while Italy and Spain are active in clinical proteomics, hospital-based diagnostics, oncology research, microbiology, and food safety testing.

China is rapidly expanding protein detection and quantification capacity through large-scale biomedical research, biopharmaceutical manufacturing, clinical laboratory growth, and precision medicine initiatives. India is strengthening its role through biosimilar development, diagnostic manufacturing, infectious disease testing, and expanding research institutions. Japan remains highly advanced in analytical science, clinical laboratory quality, proteomics research, and automation. Australia supports protein analysis through biomedical research, clinical trials, public health laboratories, and agricultural bioscience. South Korea is advancing through biopharmaceutical innovation, hospital-based research, precision medicine programs, and strong adoption of automated analytical platforms.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay reliability, workflow automation, and data interoperability to remain competitive in protein detection and quantification. Laboratories and solution providers should invest in validated workflows that minimize sample variability, improve sensitivity, and support reproducible quantification across instruments, operators, and sites. For clinical and regulated environments, strong documentation, traceable calibration, reference standards, and quality control materials are essential to support compliance and confidence in results.

Strategic focus should be placed on multiplexing, low-volume sample analysis, AI-supported data interpretation, and integration with multi-omics platforms. Organizations should also build expertise in bioinformatics, laboratory information management, and secure data governance, as protein quantification increasingly depends on computational analysis. Partnerships with academic centers, clinical networks, public health laboratories, and biomanufacturing stakeholders can accelerate biomarker validation and application-specific assay development. To support global adoption, leaders should tailor offerings to regional needs, including high-throughput research in mature markets, cost-effective diagnostic workflows in emerging regions, and scalable quality control solutions for biologics, biosimilars, and cell and gene therapy products.

Research Methodology

This executive summary is developed through a structured secondary research methodology focused on verified, data-backed industry intelligence. The analysis considers peer-reviewed scientific literature, regulatory guidance, public health resources, government research initiatives, clinical laboratory standards, biopharmaceutical quality requirements, and documented technology trends in protein detection and quantification. Emphasis is placed on validated applications across immunoassays, mass spectrometry, chromatography, electrophoresis, fluorescence detection, biosensors, and multiplex proteomics.

The research approach includes cross-verification of thematic insights across scientific, regulatory, and industry-relevant sources to ensure consistency and practical relevance. Regional, group, and country insights are assessed using evidence related to biomedical research infrastructure, clinical laboratory development, public health priorities, biopharmaceutical activity, regulatory quality systems, and adoption of advanced analytical technologies. The methodology avoids unsupported projections and excludes market estimation, market sizing, market share, and forecasting, focusing instead on qualitative evidence, technology adoption patterns, and strategic implications for stakeholders.

Conclusion

Protein detection and quantification are becoming increasingly critical as life science and healthcare ecosystems shift toward precision medicine, biologics development, advanced diagnostics, and multi-omics research. The field is evolving from conventional single-protein assays toward automated, multiplexed, ultrasensitive, spatially resolved, and computationally integrated workflows. These advancements are improving the ability to identify disease biomarkers, characterize therapeutic proteins, monitor immune responses, and understand complex biological systems.

Future progress will depend on reproducibility, standardization, assay validation, and responsible use of artificial intelligence. Regions and countries with strong research infrastructure, clinical laboratory quality systems, and biopharmaceutical capabilities are positioned to accelerate adoption, while emerging markets are expanding access through diagnostic modernization and public health investments. Organizations that combine robust analytical performance with automation, interoperable data systems, and application-specific workflow design will be best prepared to address the growing scientific and clinical importance of protein measurement.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Protein Detection & Quantification Market, by Product Type

• 7.1. Introduction
• 7.2. Instruments
  • 7.2.1. Chromatography Systems
  • 7.2.2. Electrophoresis Systems
  • 7.2.3. Mass Spectrometers
  • 7.2.4. Surface Plasmon Resonance Systems
• 7.3. Kits And Reagents
  • 7.3.1. Kits
    • 7.3.1.1. Elisa Kits
    • 7.3.1.2. Protein Assay Kits
    • 7.3.1.3. Western Blot Kits
  • 7.3.2. Reagents
    • 7.3.2.1. Antibodies
    • 7.3.2.2. Buffers
    • 7.3.2.3. Enzymes
• 7.4. Services
  • 7.4.1. Analytical Services
  • 7.4.2. Custom Assay Development
  • 7.4.3. Data Analysis
  • 7.4.4. Outsourcing

8. Protein Detection & Quantification Market, by Sample Type

• 8.1. Introduction
• 8.2. Blood
• 8.3. Cell Culture
• 8.4. Plasma
• 8.5. Serum
• 8.6. Tissue
• 8.7. Urine

9. Protein Detection & Quantification Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Disease Research
• 9.4. Drug Discovery
• 9.5. Environmental Testing
• 9.6. Food Safety

10. Protein Detection & Quantification Market, by End User

• 10.1. Introduction
• 10.2. Academic Institutions
• 10.3. Biotech Companies
• 10.4. Contract Research Organizations
• 10.5. Hospitals & Clinics
• 10.6. Pharmaceutical Companies

11. Protein Detection & Quantification Market, by Region

• 11.1. Asia-Pacific
• 11.2. Europe
• 11.3. North America
• 11.4. Latin America
• 11.5. Africa
• 11.6. Middle East

12. Protein Detection & Quantification Market, by Group

• 12.1. NATO
• 12.2. G7
• 12.3. BRICS
• 12.4. European Union
• 12.5. ASEAN
• 12.6. GCC

13. Protein Detection & Quantification Market, by Country

• 13.1. China
• 13.2. United States
• 13.3. Japan
• 13.4. India
• 13.5. Germany
• 13.6. United Kingdom
• 13.7. Australia
• 13.8. France
• 13.9. South Korea
• 13.10. Italy
• 13.11. Canada
• 13.12. Russia
• 13.13. Brazil
• 13.14. Mexico
• 13.15. Spain

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Agilent Technologies, Inc.
• 15.2. Bio-Rad Laboratories, Inc.
• 15.3. Bio-Techne Corporation
• 15.4. Biognosys AG
• 15.5. Charles River Laboratories International, Inc.
• 15.6. Danaher Corporation
• 15.7. Elabscience Biotechnology Inc.
• 15.8. GE HealthCare Technologies Inc.
• 15.9. Kaneka Eurogentec S.A.
• 15.10. Megazyme Limited
• 15.11. Merck KGaA
• 15.12. Promega Corporation
• 15.13. Revvity, Inc.
• 15.14. Shimadzu Corporation
• 15.15. Takara Bio Inc.
• 15.16. Thermo Fisher Scientific Inc.
• 15.17. Waters Corporation